New frontiers in therapeutic resistance in cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 7, 2012, Pages 877-879

  Sartore Bianchi, Andrea ^a   Delorenzi, Mauro ^b,c   Gagnon Kugler, Thérèse ^d   Rousseau, Caroline ^e   Batist, Gerald ^e  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d LAVAL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

ALK inhibitors; anti EGFR antibodies; BATTLE trial; bioinformatics; biomarkers; biopsy driven trials; BRAF inhibitors; drug resistance; I SPY trial; personalized medicine; tumor heterogeneity

Indexed keywords

CRIZOTINIB; TUMOR MARKER; VEMURAFENIB;

BREAST CANCER; CANCER RESEARCH; CANCER RESISTANCE; CELL HETEROGENEITY; CONFERENCE PAPER; DATA ANALYSIS; GENE MUTATION; GENOMICS; HUMAN; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PUBLIC-PRIVATE PARTNERSHIP; TUMOR BIOPSY; TUMOR RESISTANCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PROTEOMICS; TREATMENT OUTCOME;

EID: 84864612510     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.71     Document Type: Conference Paper

References (15)

1. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973-977 (2010).
2. Shi H, Moriceau G, Kong X et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 3, 724 (2012).
3. Atefi M, von Euw E, Attar N et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE 6(12), e28973 (2011).
4. Cavazzoni A, Bonelli MA, Fumarola C et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/ mTOR pathway in breast cancer cell clones. Cancer Lett. 323(1), 77-87 (2012).
5. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.43 (2012) (Epub ahead of print).
6. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18(5), 1472-1482 (2012).
7. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 4(10), e7287 (2009).
8. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1(6), 15 (2011).
9. Ruiz C, Lenkiewicz E, Evers L et al. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc. Natl Acad. Sci. USA 108(29), 12054-12059 (2011).
10. Kim E, Herbst R, Wistuba I et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 1(1), 9 (2011).
11. Esserman LJ, Berry DA, Cheang MC et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res. Treat. 132(3), 1049-1062 (2012).
12. Diaz Z, Aguilar-Mahecha A, Basik M et al. Determining optimal conditions for collection and processing of metastatic liver biopsies collected for a multicenter, prospective study to identify biomarkers of clinical resistance to first-line therapy in metastatic colorectal cancer. Presented at: Aacr Annual Meeting. Chicago, IL, USA, 31 March-4 April 2012.
13. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
14. Venkata N, Kontro M, Edgren H et al. Personalized treatment selection for therapy-resistant AML by integrating ex-vivo drug sensitivity and resistance testing (DSRT) as well as serial genomic, transcriptomic and phosphoproteomic profiling. Presented at: Aacr Annual Meeting. Chicago, IL, USA, 31 March-4 April 2012.
15. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 17(6), 528-536 (2011).